Research
Hormonal
Once-weekly GLP-1RA therapy can produce substantial weight loss over prolonged treatment (up to 23% at 72 weeks), alongside improvements in metabolic outcomes and reduced cardiometabolic risk.
GLP-1RA therapies can be effective for significant weight loss and improving metabolic health in obese patients.
StrongSupportsmedium confidence
Once-weekly GLP-1RA therapy can produce substantial weight loss over prolonged treatment (up to 23% at 72 weeks), alongside improvements in metabolic outcomes and reduced cardiometabolic risk.
Why this rating
The claim is based on findings from multiple studies referenced in the abstract.
Source
Body composition matters: Preserving muscle and function in the era of GLP‐1‐based weight loss therapies
Eric B. Emanuelsson et al. · The Journal of Physiology · 2025
DOI 10.1113/jp290350
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →